MedTrace Logo

Complex Cutaneous Leishmaniasis Healing Study in Algeria

NCT03292835 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-08-03

No results posted yet for this study

Summary

This study evaluates the effect of clean wound management and dressing on complex zoonotic cutaneous leishmaniasis caused by L. major in the MENA region (Algeria). The patients will participate in the wound dressing themselves. The objective is to determine the amount of patients that can avoid systemic chemotherapy with pentavalent antimony which is compulsory for patients with complex CL lesions. In Algeria, this requires expensive hospital care because of the eventual toxic side effects of Sb(V).

Conditions

  • Cutaneous Leishmaniases

Interventions

DEVICE

LeiProtect®

Filmogenic dressing gel

Sponsors & Collaborators

  • Institut Pasteur

    collaborator INDUSTRY

  • University of Erlangen-Nürnberg Medical School

    collaborator OTHER

  • K. W. Stahl

    lead OTHER

Principal Investigators

  • Zoubir Harrat, Dr. · Pasteur Institute

Eligibility

Min Age
1 Week
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2020-11-15
Completion
2020-11-15

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03292835 on ClinicalTrials.gov